decentralized clinical trials
-
Managing the Proliferation of Data From Decentralized Trials: A Successful Path Forward
As the industry focuses on creating a more holistic, inclusive experience, these three focus areas can help bridge the gap between patient, site, and clinical research administrators and help to modernize the clinical trial experience for all.
-
MedCity Influencers, Legal, Health Tech
New FDA Draft Guidance Signals Acceptance of Decentralized Trials (When Done Right)
he FDA has made a purposeful choice to write in broad strokes, stopping short of detailing ways to execute DCTs. Even so, the Agency is starting to acknowledge – and thereby support – the global shift towards expanded trial models. Essentially, the FDA is implicitly broadening the definition of clinical trials.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
CVS’ Shuttered Clinical Trials Business Doesn’t Mean Decentralized Models Are Doomed, Exec Says
CVS Health is winding down its clinical trials business, with a full exit expected by December 31, 2024, the company confirmed to MedCity News. But decentralized clinical trials still have an important role to play, said Brian Weiss, CEO of Carebox.
-
FDA’s Landmark Guidance on Decentralized Clinical Trials (DCTs) Signals a New Era of Patient-Centered Research
With the FDA’s acceptance and encouragement of decentralized trials, we can expect to see a continued shift towards remote trial conduct, virtual sites, and the use of innovative digital technologies.
-
How Will FDA Guidance Impact Decentralized Clinical Trials in 2023?
The agency’s goal is to spur a macro shift in clinical trials. The FDA is trying to tell these companies what it wants to be different in trials across the board with regards to digital health endpoints, the use of real-world data (RWD) as regulatory-grade data, and diversity in clinical trial inclusion.
-
MedCity Influencers, Consumer / Employer
Patient Voice and Patient Choice: Essentials for Successful DCTs
Historically, clinical trials have not prioritized the experiences of patients, who are required to frequently return on-site and engage with unfamiliar medical technology. They are often left in the dark regarding the data and health outcomes being collected through their participation.
-
Putting Patients First: Seeking To Solve Long-standing Challenges With Clinical Research Participation and Access
Clinical research as a care option is a means of connecting patients with clinical research as part of their ongoing health care, located where they receive that care, and offered by their trusted provider.
-
MedCity Influencers, BioPharma
The Key To Faster, More Efficient Clinical Trials? Patient Centricity
Added complexity to daily life is likely why patient dropout rates remain high, with 19% leaving studies before completion. Truly patient-centric trials will allow for broader participation, allowing patients to decide how and when they want to engage in a study.
-
MedCity Influencers, Devices & Diagnostics, BioPharma
Silver lining: Pandemic learnings propel decentralized trial approaches for patients
Two decentralized clinical trial methodologies that are “low-hanging fruit” include automating data integration for patient trial selection and establishing standardized, electronic clinical trial templates and procedures.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
How to make community-based clinical trials a reality
When patients can travel to a pharmacy or doctor’s office in their own neighborhood, they can reach the site on foot or using public transit. They also have to take less time off work and request childcare less often.
-
Medable rolls out new decentralized trial software for speedier vaccine development
Medable recently launched a software solution to shorten the launch times for decentralized vaccine trials. The company says the software can reduce trial deployment timelines from more than 12 weeks on average to as short as five weeks.
-
Digital transformation: Reimagining clinical trial management
Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there’s a need for a hybrid approach to decentralized clinical trials that considers the perspectives of patients and the impact to clinical trial sites.
-
Improving health equity through decentralized clinical trials
A recent webinar by Medable discussed steps it’s taking to improve clinical trial design through decentralized clinical trials
-
Which clinical trial innovation startups will present at INVEST PharmaTech Pitch Perfect?
The Pitch Perfect contest at MedCity INVEST PharmaTech, the free virtual conference scheduled for July 26, will spotlight five startups seeking to improve clinical trials.
-
Google Cloud exec: Real-world data could eliminate the need for placebos in clinical trials
The speed of Covid-19 vaccine trials should inspire the pharmaceutical and medical device industries to accelerate its clinical testing, according to Shweta Maniar, Google Cloud’s director for healthcare and life sciences. She argued that harnessing real-world data will make faster clinical trials achievable for all therapeutics and devices, possibly even eliminating the need to recruit a placebo arm.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
